Class II โ€” Potential Health Hazard

Potential health hazard โ€” use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Duloxetine Delayed-Release Capsules Recalled by Breckenridge Pharmaceutical, Inc Due to CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA...

Date: April 29, 2024
Company: Breckenridge Pharmaceutical, Inc
Status: Ongoing
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Breckenridge Pharmaceutical, Inc directly.

Affected Products

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, (a) 90-count bottles (NDC 51991-747-90), (b) 1000-count bottles (NDC 51991-747-10), Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Quantity: 281,554/90 & 1000 count bottles

Why Was This Recalled?

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About Breckenridge Pharmaceutical, Inc

Breckenridge Pharmaceutical, Inc has 20 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report